Physician

Pablo M Gonzalez, M.D.

According to 2025 Medicare claims, Pablo Gonzalez, M.D. (NPI: 1124080759) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Chesterfield, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23235-4730.

Gonzalez's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 623 traditional Medicare patients, billed 99,822 HCPCS/CPT codes, and received $2,267,324 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,012 prescription claims across 137 beneficiaries totaling $4,644,586 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 70 claims. Open Payments data shows 33 records totaling $930. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,491,598 to $4,644,586. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	852	122,870	$1,764,510
2016	841	105,194	$1,889,006
2017	871	127,324	$2,105,776
2018	922	168,086	$2,663,962
2019	947	180,872	$3,006,753
2020	855	146,640	$2,969,235
2021	732	112,895	$2,359,932
2022	677	127,323	$2,639,802
2023	659	144,428	$3,068,992
2024	623	99,822	$2,267,324

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	166	989	$1,491,598
2016	170	896	$1,384,384
2017	177	908	$1,257,100
2018	161	999	$1,939,295
2019	161	895	$1,978,622
2020	154	1,060	$2,863,889
2021	149	1,038	$3,871,356
2022	146	1,002	$4,307,598
2023	127	901	$4,647,436
2024	137	1,012	$4,644,586

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	235	$11,465
2016	N/R	105	$14,453
2017	N/R	60	$7,752
2018	N/R	61	$8,621
2019	N/R	N/R	N/R
2020	N/R	14	$267
2021	N/R	12	$230
2022	N/R	N/R	N/R
2023	N/R	16	$301
2024	N/R	70	$1,719

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	100	285	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	228	683	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	269	398	$62
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	80	150	$45
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	241	387	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	68	1,972	$995,742
Pomalyst	Pomalidomide	31	868	$681,419
Calquence	Acalabrutinib Maleate	40	1,200	$573,516
Cabometyx	Cabozantinib S-Malate	22	660	$537,214
Venclexta	Venetoclax	16	480	$241,861

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	13	$636
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$414
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	22	$376
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$201
J8520	Capecitabine, oral, 150 mg	N	N/R	11	$92

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	33	$930	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Pablo M. Gonzalez, M.D.?

Tedicare shows public-source Medicare data for Pablo M. Gonzalez, M.D. (NPI 1124080759), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Pablo M. Gonzalez, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Pablo M. Gonzalez, M.D.?

Pablo M. Gonzalez, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Pablo M. Gonzalez, M.D. have Open Payments data?

Pablo M. Gonzalez, M.D. has 33 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.